Refining chimeric antigen receptors via barcoded protein domain combination pooled screening
Molecular Therapy · 2023-11 · 31 (11) · 3210-3224
DOI: 10.1016/j.ymthe.2023.09.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2023-11. Verfasst von Xavier Rios und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced Innate Cell Therapy, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Cent…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, Alex's Lemonade Stand Foundation for Childhood Cancer.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)-T cells represent a promising frontier in cancer immunotherapy. However, the current process for developing new CAR constructs is time consuming and inefficient. To address this challenge and expedite the evaluation and comparison of full-length CAR designs, we have devised a novel cloning strategy. This strategy involves the sequential assembly of individual CAR domains using blunt ligation, with each domain being assigned a unique DNA barcode. Applying this method, we successfully generated 360 CAR constructs that specifically target clinically validated tumor antigens CD19 and GD2. By quantifying changes in barcode frequencies through next-generation sequencing, we characterize CARs that best mediate proliferation and expansion of transduced T cells. The screening revealed a crucial role for the hinge domain in CAR functionality, with CD8a and IgG4 hinges having opposite effects in the surface expression, cytokine production, and antitumor activity in CD19- versus GD2-based CARs. Importantly, we discovered two novel CD19-CAR architectures containing the IgG4 hinge domain that mediate superior in vivo antitumor activity compared with the construct used in Kymriah, a U.S. Food and Drug Administration (FDA)-approved therapy. This novel screening approach represents a major advance in CAR engineering, enabling accelerated development of cell-based cancer immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Advanced Innate Cell Therapy, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX,…
- Center for Advanced Innate Cell Therapy, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
- Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- Alex's Lemonade Stand Foundation for Childhood Cancer
Zitieren
APA
Rios, X., Pardias, O., Morales, M. A., Bhattacharya, P., Chen, Y., Guo, L., Zhang, C., Di Pierro, E. J., Tian, G., Barragan, G. A., Sumazin, P., & Metelitsa, L. S. (2023). Refining chimeric antigen receptors via barcoded protein domain combination pooled screening. Molecular Therapy, 31(11), 3210-3224. https://doi.org/10.1016/j.ymthe.2023.09.008
Vancouver
Rios X, Pardias O, Morales MA, Bhattacharya P, Chen Y, Guo L, et al. Refining chimeric antigen receptors via barcoded protein domain combination pooled screening. Molecular Therapy. 2023;31(11):3210-3224. doi:10.1016/j.ymthe.2023.09.008
BibTeX
@article{Rios2023,
author = {Rios, Xavier and Pardias, Osmay and Morales, Marc A and Bhattacharya, Pradyot and Chen, Yibin and Guo, Linjie and Zhang, Chunchao and Di Pierro, Erica J and Tian, Gengwen and Barragan, Gabriel A and Sumazin, Pavel and Metelitsa, Leonid S},
title = {Refining chimeric antigen receptors via barcoded protein domain combination pooled screening},
journal = {Molecular Therapy},
year = {2023},
volume = {31},
number = {11},
pages = {3210--3224},
doi = {10.1016/j.ymthe.2023.09.008}
}
EUVIMED